| Identification | Back Directory | [Name]
Rucaparib camsylate | [CAS]
1327258-57-0 | [Synonyms]
Asciminib Impurity 4
8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2,ef][2]benzazepin-6-one (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid | [Molecular Formula]
C29H34FN3O5S | [MDL Number]
MFCD31382198 | [MOL File]
1327258-57-0.mol | [Molecular Weight]
555.661 |
| Hazard Information | Back Directory | [Uses]
Rucaparib Camsylate is a novel PARP inhibitor. | [in vivo]
Rucaparib (AG014699) camsylate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) camsylate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) camsylate results in a 50% increase in the temozolomide-induced tumor growth delay[1].
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) camsylate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions[2].
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) camsylate has greatest antitumor effect with three complete regressions[2].
Rucaparib camsylate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts[6].
| Animal Model: | Female CD-1 nude mice aged 10-12 weeks with Capan-1 cells[2] | | Dosage: | 10?mg/kg or 50, 150 mg/kg | | Administration: | 10?mg/kg for i.p. or 50, 150 mg/kg for p.o. | | Result: | Significantly inhibited the growth of the tumor. |
| [IC 50]
PARP-1: 1.4 nM (Ki); PARP-2; PARP-3 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|